Tagrisso Prices, Coupons, Copay Cards & Patient Assistance
Tagrisso (osimertinib) is a member of the EGFR inhibitors drug class and is commonly used for Non Small Cell Lung Cancer.
Tagrisso is available as a brand name drug only, a generic version is not yet available. View generic Tagrisso availability for more details.
Tagrisso prices
Oral Tablet
80 mg Tagrisso oral tablet from $17,229.65 for 30 tablets
| Quantity | Per unit | Price |
|---|---|---|
| 30 | $574.32 | $17,229.65 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
Get your FREE Drugs.com Discount Card
Save up to 80% off the cost of prescription drugs and OTC medicines valid at over 65,000 pharmacies.
This is a drug discount program, not an insurance plan.
Tagrisso Coupons, Copay Cards and Rebates
Tagrisso offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.
Tagrisso Access 360 Co-pay Savings Program
Eligible commercially insured patients may pay $0 per 28-day supply with savings of up to $26,000 per year.
- Applies to:
- Tagrisso
- Number of uses:
- Per prescription per year
Form more information phone: 844-275-2360 or Visit website
Patient Assistance & Copay Programs for Tagrisso
Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.
Provider: AZ&Me Prescription Savings Program for people without insurance
Eligibility requirements:- Must have no prescription coverage for needed medication
- Varies
- Not required
- The patient must also be a US resident.
- People who are in Medicare and may be eligible for the Limited Income Subsidy can apply. However, if they are accepted into the LIS, they are no longer eligible for the AZ& Me Prescription Savings Program. Eligibility determined on a case-by-case basis.
- Tagrisso (osimertinib) Tablet
More information please phone: 800-292-6363 Visit website
Provider: AZ&Me Prescription Savings Program for people with Medicare Part D
Eligibility requirements:- Contact program for details.
- Varies
- Not required
- The patient must also be a US resident.
- Eligibility determined on a case-by-case basis. *Patient must participate in Medicare Part B, Medicare Part D or Medicare Advantage This program may provide a Bridge Program for eligible patients who experience a delay, temporary loss, or change in coverage. Contact program for details.
- Tagrisso (osimertinib) Tablet
More information please phone: 800-292-6363 Visit website
Provider: Patient Access Network Foundation (PAN)
Eligibility requirements:- *See Additional Information section below
- Between 400-500% of FPL
- FDA Approved Diagnosis - See Program Website for Details
- Must reside and receive treatment in US
- *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.
- Tagrisso (osimertinib) Tablet
More information please phone: 866-316-7263 Visit website
Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.
See also:
More about Tagrisso (osimertinib)
- Check interactions
- Compare alternatives
- Reviews (38)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: EGFR inhibitors
- Breastfeeding
- En español